




# Drug Profiles

As Recommended by the Bureau of EMS and Trauma System



**ADHS**

---

PREPAREDNESS

**Arizona Department of Health Services**

These guidelines are designed to be a resource document for use by Medical Direction Authorities, as defined by A.R.S. § 36-2205, responsible for the administrative, organizational and on-line medical direction of pre-hospital Emergency Medical Care Technicians (EMCTs). It is specifically recognized that documented regional or local variations from the guidelines contained within are not only acceptable, but also appropriate, depending on the individual circumstances of the involved areas and organizations.

By Statute and Rule, all advanced life support pre-hospital EMCTs shall have administrative and on-line medical direction. These guidelines are not meant to act as a substitute, proxy or alternative to that medical direction. Any conflict between these guidelines and the EMCT's medical direction shall default to the Administrative or on-line medical direction.

These guidelines are deemed by the Bureau of EMS and Trauma System to be within the acceptable standard of medical care. It is specifically recognized that there are acceptable documented regional or local variations from these procedures and protocols, which may also satisfy the standard of care. This manual does NOT define, limit, expand, or otherwise purport to establish the legal standard of care.

Title	Page	Title	Page
<a href="#">Adenosine</a>	5	<a href="#">Hydroxocobalamin aka Cyanokit</a>	26
<a href="#">Albuterol Sulfate</a>	6	<a href="#">Ipratropium Bromide</a>	27
<a href="#">Amiodarone</a>	7	<a href="#">Ketamine</a>	28
<a href="#">Aspirin, Acetylsalicylic Acid, ASA</a>	8	<a href="#">Lidocaine</a>	29
<a href="#">Atropine Sulfate</a>	9	<a href="#">Lorazepam</a>	30
<a href="#">Atropine &amp; pralidoxime (combined) autoinjector (DuoDote®)</a>	10	<a href="#">Magnesium Sulfate</a>	31
<a href="#">Calcium Chloride</a>	11	<a href="#">Methylene blue</a>	32
<a href="#">Calcium Gluconate 2.5% topical gel</a>	12	<a href="#">Methylprednisolone Sodium Succinate</a>	33
<a href="#">Calcium Gluconate</a>	13	<a href="#">Midazolam</a>	34
<a href="#">Dexamethasone Sodium Phosphate</a>	14	<a href="#">Morphine Sulfate</a>	35
<a href="#">Dextrose</a>	15	<a href="#">Naloxone</a>	36
<a href="#">Diazepam</a>	16	<a href="#">Nitroglycerin</a>	37
<a href="#">Diltiazem</a>	17	<a href="#">Norepinephrine</a>	38
<a href="#">Diphenhydramine</a>	18	<a href="#">Ondansetron</a>	39
<a href="#">Dopamine (2 pages)</a>	19-20	<a href="#">Oxytocin</a>	40
<a href="#">Epinephrine</a>	21	<a href="#">Phenylephrine Nasal Spray 0.5%</a>	41
<a href="#">Etomidate</a>	22	<a href="#">Pralidoxime Autoinjector</a>	42
<a href="#">Fentanyl</a>	23	<a href="#">Proparacaine Ophthalmic</a>	43
<a href="#">Glucagon</a>	24	<a href="#">Propranolol</a>	44
<a href="#">Glucose</a>	25	<a href="#">Rocuronium</a>	45

Drugs listed as IV administration can be given IO.

Title	Page	Title	Page
<a href="#">Sodium bicarbonate 7.5%–8.4%</a>	46		
<a href="#">Sodium nitrite</a>	47		
<a href="#">Sodium nitrite &amp; sodium thiosulfate (combined) (Nithiodote®)</a>	48		
<a href="#">Sodium thiosulfate</a>	49		
<a href="#">Succinylcholine</a>	50		
<a href="#">Tetracaine</a>	51		
<a href="#">Thiamine (vitamin B1)</a>	52		
<a href="#">Tranexamic acid (TXA)</a>	53		

Drugs listed as IV administration can be given IO.

DRUG PROFILE		AZDHS	
Adenosine		5/21/2020	
<b>PHARMACOLOGY &amp; ACTIONS</b>			
<ul style="list-style-type: none"><li>Slows conduction through the AV node.</li><li>Most cases of PSVT involve AV nodal reentry, adenosine is capable of interrupting the AV nodal circuit and stopping the tachycardia, restoring normal sinus rhythm.</li></ul>			
<b>INDICATIONS</b>			
<ul style="list-style-type: none"><li>To convert hemodynamically stable narrow complex regular tachycardia with a pulse.</li></ul>			
<b>ABSOLUTE CONTRAINDICATIONS</b>			
<ul style="list-style-type: none"><li>Second or third degree heart block.</li><li>Poison or drug-induced tachycardia.</li><li>Known hypersensitivity.</li><li>Adenosine allergy.</li></ul>			
<b>PRECAUTIONS &amp; SIDE EFFECTS</b>			
<ul style="list-style-type: none"><li>May cause brief asystole, dizziness, facial flushing, headache, nausea, and transient shortness of breath.</li><li>IV adenosine has been shown to produce bronchospasm in asthmatic patients.</li><li>If the patient becomes hemodynamically unstable, cardioversion should occur.</li></ul>			
<b>ADMINISTRATION</b>			
IV	<b>Onset:</b> 20–30 seconds	<b>Peak Effect:</b> 20–30 seconds	<b>Duration:</b> 30 seconds
<b>GUIDELINES CONTAINING ADENOSINE</b>			
<ul style="list-style-type: none"><li><b>Tachycardia with a Pulse: Adult &amp; Pediatric</b></li></ul>			

DRUG PROFILE		AZDHS	
Albuterol Sulfate		5/21/2020	
<b>PHARMACOLOGY &amp; ACTIONS</b>			
<ul style="list-style-type: none"> <li>• Relatively selective beta2-adrenergic bronchodilator.</li> <li>• Beta-2 agonist that relaxes bronchial smooth muscle, resulting in bronchial dilation.</li> <li>• Some beta-1 overlap with clinically significant cardiac effects such as tachycardia.</li> <li>• Shift potassium intracellular, resulting in lower serum potassium.</li> </ul>			
<b>INDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Treatment of bronchospasm.</li> <li>• Treatment of hyperkalemia.</li> </ul>			
<b>ABSOLUTE CONTRAINDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Albuterol sulfate allergy.</li> </ul>			
<b>PRECAUTIONS &amp; SIDE EFFECTS</b>			
<ul style="list-style-type: none"> <li>• May cause dizziness, anxiety, palpitations, headache, sweating, and muscle tremors.</li> <li>• Clinically significant arrhythmias may occur especially in patients with underlying cardiovascular disorders.</li> <li>• Relative contraindication include symptomatic tachycardia, tachyarrhythmias , or anginal chest pain.</li> </ul>			
<b>ADMINISTRATION</b>			
SVN	Onset: 5–15 minutes	Peak Effect: 1–1.5 hours	Duration: 3–6 hours
<b>GUIDELINES CONTAINING ALBUTEROL</b>			
<ul style="list-style-type: none"> <li>• <b>Bronchospasm (due to Asthma and Obstructive Lung Disease): Adult &amp; Pediatric</b></li> <li>• <b>Anaphylaxis and Allergic Reaction: Adult &amp; Pediatric</b></li> <li>• <b>Hyperglycemia: Adult &amp; Pediatric</b></li> <li>• <b>Extremity Trauma: Adult &amp; Pediatric</b></li> <li>• <b>Dermal Chemical Burns: Adult &amp; Pediatric</b></li> </ul>			

DRUG PROFILE		AZDHS	
Amiodarone		5/21/2020	
<b>PHARMACOLOGY &amp; ACTIONS</b>			
<ul style="list-style-type: none"> <li>• Multiple effects on sodium, potassium, and calcium channels.</li> <li>• Prolongs action potential and repolarization.</li> <li>• Decreases AV conduction and sinus node function.</li> <li>• Also has some alpha- and beta-adrenergic blocking properties.</li> </ul>			
<b>INDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Ventricular fibrillation.</li> <li>• Pulseless ventricular tachycardia.</li> <li>• Regular wide complex tachycardia with a pulse.</li> <li>• Irregular wide complex tachycardia.</li> </ul>			
<b>ABSOLUTE CONTRAINDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Second or third degree AV blocks.</li> <li>• Amiodarone allergy.</li> </ul>			
<b>PRECAUTIONS &amp; SIDE EFFECTS</b>			
<ul style="list-style-type: none"> <li>• May cause hypotension and bradycardia.</li> </ul>			
<b>ADMINISTRATION</b>			
IV	Onset: 1–2 minutes	Peak Effect: 10 minutes	Duration: variable
<b>GUIDELINES CONTAINING AMIODARONE</b>			
<ul style="list-style-type: none"> <li>• <b>Cardiac Arrest (VF/VT/Asystole/PEA): Age 8 and Older</b></li> <li>• <b>Tachycardia with a Pulse: Adult &amp; Pediatric</b></li> <li>• <b>Cardiac Arrest (VF/VT/Asystole/PEA): Pediatric Age &lt; 8</b></li> </ul>			

DRUG PROFILE		AZDHS	
Aspirin / Acetylsalicylic Acid / ASA		5/21/2020	
<b>PHARMACOLOGY &amp; ACTIONS</b>			
<ul style="list-style-type: none"> <li>Aspirin inhibits prostaglandin and disrupts platelet function.</li> <li>It is also a mild analgesic and anti-inflammatory.</li> </ul>			
<b>INDICATIONS</b>			
<ul style="list-style-type: none"> <li>Adult patients with suspected acute coronary syndrome.</li> </ul>			
<b>ABSOLUTE CONTRAINDICATIONS</b>			
<ul style="list-style-type: none"> <li>Active GI bleeding.</li> <li>If patient has taken 324 mg within the last 24 hours.</li> <li>Aspirin allergy.</li> </ul>			
<b>PRECAUTIONS &amp; SIDE EFFECTS</b>			
<ul style="list-style-type: none"> <li>May cause GI discomfort and nausea.</li> <li>May cause wheezing.</li> </ul>			
<b>ADMINISTRATION</b>			
Oral	<b>Onset:</b> 5–30 minutes	<b>Peak Effect:</b> 1–2 hours	<b>Duration:</b> 4–6 hours
<b>GUIDELINES CONTAINING ASPIRIN</b>			
<ul style="list-style-type: none"> <li><b>Chest Pain/Acute Coronary Syndrome/ST-segment Elevation Myocardial Infarction (STEMI): Adult</b></li> </ul>			



DRUG PROFILE		AZDHS	
Atropine Sulfate		5/21/2020	
<b>PHARMACOLOGY &amp; ACTIONS</b>			
<ul style="list-style-type: none"> <li>Blocks action of acetylcholine as competitive antagonist at muscarinic receptor sites in smooth muscle, secretory glands, and the CNS.</li> <li>Blocks parasympathetic response, allowing sympathetic response to take over.</li> <li>Positive chronotropic properties with little to no inotropic effects. <ul style="list-style-type: none"> <li>Increases heart rate.</li> <li>Increases conduction through AV node.</li> </ul> </li> <li>Atropine reverses the muscarinic effects of cholinergic poisoning by the following mechanisms: <ul style="list-style-type: none"> <li>Reverses bronchorrhea and bronchoconstriction.</li> <li>Reduces motility and tone of GI tract.</li> <li>Reduces action and tone of the urinary bladder (may cause urinary retention).</li> <li>Dilates pupils.</li> <li>Decreases sweat production.</li> </ul> </li> </ul>			
<b>INDICATIONS</b>			
<ul style="list-style-type: none"> <li>Symptomatic bradycardia.</li> <li>Nerve agent/organophosphate and carbamate insecticide toxicity.</li> </ul>			
<b>ABSOLUTE CONTRAINDICATIONS</b>			
<ul style="list-style-type: none"> <li>Bradycardia without evidence of cardiopulmonary compromise.</li> <li>Atropine allergy.</li> </ul>			
<b>PRECAUTIONS &amp; SIDE EFFECTS</b>			
<ul style="list-style-type: none"> <li>Avoid in hypothermic bradycardia.</li> <li>Paradoxical bradycardia may result from doses less than 0.5 mg, use in caution in pediatric patients.</li> </ul>			
<b>ADMINISTRATION</b>			
IV/IM	<b>Onset:</b> immediate	<b>Peak Effect:</b> 2–4 minutes	<b>Duration:</b> 4 hours
<b>GUIDELINES CONTAINING ATROPINE</b>			
<ul style="list-style-type: none"> <li><b>Bradycardia: Adult &amp; Pediatric</b></li> <li><b>Acetylcholinesterase Inhibitor Poisoning (Nerve Agents, Organophosphates, and Carbamates): Adult &amp; Pediatric</b></li> </ul>			

DRUG PROFILE		AZDHS	
<b>Atropine &amp; pralidoxime (combined) autoinjector (DuoDote®) 1/20/2022</b>			
<b>PHARMACOLOGY &amp; ACTIONS</b>			
<ul style="list-style-type: none"> <li>• Pralidoxime reactivates acetylcholinesterase which has been inactivated by phosphorylation due to an organophosphorus nerve agent or insecticide. Reactivation is clinically important because only a small proportion of active acetylcholinesterase is needed to maintain vital functions.</li> </ul>			
<b>INDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Indicated for the treatment of poisoning by organophosphorus nerve agents as well as organophosphorus insecticides.</li> </ul>			
<b>ABSOLUTE CONTRAINDICATIONS</b>			
<ul style="list-style-type: none"> <li>• None.</li> </ul>			
<b>PRECAUTIONS</b>			
<ul style="list-style-type: none"> <li>• Pralidoxime is not effective in the treatment of poisoning due to phosphorus, inorganic phosphates, or organophosphates not having anticholinesterase activity.</li> <li>• Pralidoxime is not indicated as an antidote for intoxication by pesticides of the carbamate class since it may increase the toxicity of carbaryl.</li> </ul>			
<b>ADMINISTRATION</b>			
IM/IV/IO	<b>Onset:</b> Within 16 mins.	<b>Peak Effect:</b> 35 minutes.	<b>Duration:</b> 4 hours.
<b>GUIDELINES CONTAINING ATROPINE &amp; PRALIDOXIME (COMBINED) AUTOINJECTOR</b>			
<ul style="list-style-type: none"> <li>• <b>Acetylcholinesterase Inhibitor Poisoning (Nerve Agents, Organophosphates, and Carbamates): Adult &amp; Pediatric</b></li> </ul>			

DRUG PROFILE		AZDHS	
Calcium Chloride		5/21/2020	
<b>PHARMACOLOGY &amp; ACTIONS</b>			
<ul style="list-style-type: none"> <li>Increases extracellular and intracellular calcium levels.</li> <li>Stimulates release of catecholamines.</li> <li>Increases cardiac contractile state (positive inotropic effect).</li> <li>Essential to a number of physiologic processes including transmission of nerve impulses, contraction of cardiac, smooth and skeletal muscles.</li> <li>Has stabilizing effect on myocardial cell membranes in setting of hyperkalemia.</li> </ul>			
<b>INDICATIONS</b>			
<ul style="list-style-type: none"> <li>Suspected hyperkalemia.</li> <li>Antidote for calcium channel blocker overdose.</li> </ul>			
<b>ABSOLUTE CONTRAINDICATIONS</b>			
<ul style="list-style-type: none"> <li>Do not use in setting of suspected digoxin toxicity.</li> <li>Hypercalcemia.</li> <li>Suspected severe hypokalemia (life-threatening cardiac arrhythmias may occur).</li> <li>Calcium chloride allergy.</li> </ul>			
<b>PRECAUTIONS &amp; SIDE EFFECTS</b>			
<ul style="list-style-type: none"> <li>May cause discomfort at injection site.</li> <li>Will precipitate if mixed with sodium bicarbonate.</li> </ul>			
<b>ADMINISTRATION</b>			
IV	<b>Onset:</b> immediate	<b>Peak Effect:</b> unknown	<b>Duration:</b> varies
<b>GUIDELINES CONTAINING CALCIUM CHLORIDE</b>			
<ul style="list-style-type: none"> <li><b>Hyperglycemia: Adult &amp; Pediatric</b></li> <li><b>Cardiac Arrest (VF/VT/Asystole/PEA): Age 8 and Older</b></li> <li><b>Cardiac Arrest (VF/VT/Asystole/PEA): Pediatric Age &lt; 8</b></li> <li><b>Extremity Trauma: Adult &amp; Pediatric</b></li> <li><b>Dermal Chemical Burns: Adult &amp; Pediatric</b></li> </ul>			

DRUG PROFILE		AZDHS	
<b>Calcium Gluconate 2.5% Topical Gel</b>		5/21/2020	
<b>PHARMACOLOGY &amp; ACTIONS</b>			
<ul style="list-style-type: none"> <li>• Calcium gluconate combines with hydrofluoric acid to neutralize the fluoride ion, forming insoluble calcium fluoride.</li> <li>• This helps stop the fluoride ion from penetrating into tissue and bone, preventing further damage.</li> <li>• The gel does NOT treat or heal HF burns that have already developed.</li> </ul>			
<b>INDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Used after contact with hydrofluoric acid to mitigate or prevent the related pain and potential tissue burns and bone damage.</li> </ul>			
<b>ABSOLUTE CONTRAINDICATIONS</b>			
<ul style="list-style-type: none"> <li>• For cutaneous/skin application only.</li> <li>• Calcium gluconate allergy.</li> </ul>			
<b>PRECAUTIONS &amp; SIDE EFFECTS</b>			
<ul style="list-style-type: none"> <li>• Personnel should wear appropriate HF-protective gloves (neoprene) and other safety equipment before assisting patient with application of gel.</li> <li>• If possible, the patient should wash area and apply the gel themselves.</li> <li>• Consider placing surgical glove over gel when applied to distal upper extremities.</li> </ul>			
<b>ADMINISTRATION</b>			
	<b>Onset:</b> immediate	<b>Peak Effect:</b> varies	<b>Duration:</b> unknown
<b>GUIDELINES CONTAINING CALCIUM GLUCONATE GEL</b>			
<ul style="list-style-type: none"> <li>• <b>Dermal Chemical Burns: Adult &amp; Pediatric</b></li> </ul>			

DRUG PROFILE		AZDHS	
Calcium Gluconate		5/21/2020	
<b>PHARMACOLOGY &amp; ACTIONS</b>			
<ul style="list-style-type: none"> <li>Increases extracellular and intracellular calcium levels.</li> <li>Stimulates release of catecholamines.</li> <li>Increases cardiac contractile state (positive inotropic effect).</li> <li>Essential to a number of physiologic processes including transmission of nerve impulses, contraction of cardiac, smooth and skeletal muscles.</li> <li>Has stabilizing effect on myocardial membranes in setting of hyperkalemia.</li> </ul>			
<b>INDICATIONS</b>			
<ul style="list-style-type: none"> <li>Suspected hyperkalemia.</li> <li>Calcium channel blocker overdose.</li> </ul>			
<b>ABSOLUTE CONTRAINDICATIONS</b>			
<ul style="list-style-type: none"> <li>Do not use in the setting of suspected digoxin toxicity.</li> <li>Hypercalcemia.</li> <li>Sarcoidosis.</li> <li>Suspected severe hypokalemia (life-threatening cardiac arrhythmias may occur).</li> <li>Calcium gluconate allergy.</li> </ul>			
<b>PRECAUTIONS &amp; SIDE EFFECTS</b>			
<ul style="list-style-type: none"> <li>Risk of digitalis toxicity.</li> <li>SQ or IM administration can cause severe tissue necrosis and tissue sloughing.</li> <li>Can induce serious cardiac dysrhythmias.</li> </ul>			
<b>ADMINISTRATION</b>			
IV	Onset: 1–3 minutes	Peak Effect: immediate	Duration: 30–120 minutes
<b>GUIDELINES CONTAINING CALCIUM GLUCONATE</b>			
<ul style="list-style-type: none"> <li><b>Hyperglycemia: Adult &amp; Pediatric</b></li> <li><b>Cardiac Arrest (VF/VT/Asystole/PEA): Age 8 and Older</b></li> <li><b>Cardiac Arrest (VF/VT/Asystole/PEA): Pediatric Age &lt;8</b></li> <li><b>Extremity Trauma: Adult &amp; Pediatric</b></li> <li><b>Dermal Chemical Burns: Adult &amp; Pediatric</b></li> </ul>			

DRUG PROFILE		AZDHS	
Dexamethasone Sodium Phosphate		5/21/2020	
<b>PHARMACOLOGY &amp; ACTIONS</b>			
<ul style="list-style-type: none"><li>• Improves lung function and myocardial performance.</li><li>• Stabilization of lysosomal and cell membranes, inhibition of compliment-induced granulocyte aggregation.</li><li>• Rightward shift in oxygen-hemoglobin dissociation curve.</li><li>• Inhibition of prostaglandin and leukotriene production, increase in surfactant production, decrease in pulmonary edema, relaxation of bronchospasm.</li></ul>			
<b>INDICATIONS</b>			
<ul style="list-style-type: none"><li>• Reactive airway disease: Acute exacerbation of bronchial asthma.</li><li>• Anaphylaxis.</li></ul>			
<b>ABSOLUTE CONTRAINDICATIONS</b>			
<ul style="list-style-type: none"><li>• Systemic fungal infections.</li><li>• Preterm infants.</li><li>• Dexamethasone allergy.</li></ul>			
<b>PRECAUTIONS &amp; SIDE EFFECTS</b>			
<ul style="list-style-type: none"><li>• If given IV should be given as slow IV push.</li><li>• Sodium retention, fluid retention, potassium loss, hypokalemic alkalosis, hypertension, convulsions, hyperglycemia, myocardial rupture following recent myocardial infarction.</li></ul>			
<b>ADMINISTRATION</b>			
IV/IM	Onset: 4–8 hours	Peak Effect: 6–12 hours	Duration: 24–72 hours
<b>GUIDELINES CONTAINING DEXAMETHASONE</b>			
<ul style="list-style-type: none"><li>• <b>Bronchospasm (due to Asthma and Obstructive Lung Disease): Adult &amp; Pediatric</b></li><li>• <b>Pediatric Stridor (e.g., Croup)</b></li></ul>			

DRUG PROFILE		AZDHS	
Dextrose		5/21/2020	
<b>PHARMACOLOGY &amp; ACTIONS</b>			
<ul style="list-style-type: none"> <li>Rapidly increases blood glucose.</li> </ul>			
<b>INDICATIONS</b>			
<ul style="list-style-type: none"> <li>Hypoglycemia.</li> </ul>			
<b>ABSOLUTE CONTRAINDICATIONS</b>			
<ul style="list-style-type: none"> <li>None in prehospital setting.</li> <li>Dextrose allergy.</li> </ul>			
<b>PRECAUTIONS &amp; SIDE EFFECTS</b>			
<ul style="list-style-type: none"> <li>Extravasation of dextrose may cause tissue necrosis.</li> <li>Use caution during administration.</li> <li>If extravasation does occur, immediately stop administration of drug.</li> <li>Report extravasation of the medication to receiving hospital personnel and document.</li> <li>If there is any evidence of malnutrition or alcohol abuse, thiamine, if available, should precede the administration of dextrose (adult patients only).</li> </ul>			
<b>ADMINISTRATION</b>			
IV	Onset: < 1 minute	Peak Effect: variable	Duration: variable
<b>PROTOCOLS CONTAINING DEXTROSE</b>			
<ul style="list-style-type: none"> <li><b>Hypoglycemia: Adult &amp; Pediatric</b></li> </ul>			

DRUG PROFILE		AZDHS	
Diazepam		5/21/2020	
<b>PHARMACOLOGY &amp; ACTIONS</b>			
<ul style="list-style-type: none"> <li>• Benzodiazepine drug.</li> <li>• Decreases seizures by increasing the seizure threshold.</li> <li>• Sedative.</li> <li>• Amnestic effect.</li> </ul>			
<b>INDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Active seizures.</li> <li>• Sedation prior to cardioversion, cardioversion, etc.</li> </ul>			
<b>ABSOLUTE CONTRAINDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Severe respiratory depression.</li> <li>• Diazepam allergy.</li> </ul>			
<b>PRECAUTIONS &amp; SIDE EFFECTS</b>			
<ul style="list-style-type: none"> <li>• Since diazepam can cause respiratory depression and/or hypotension, the patient must be monitored closely. Diazepam should not be given to adult patients without a good IV line in place and a bag valve mask ready.</li> <li>• Paradoxical excitement or stimulation sometimes occurs.</li> <li>• Most likely to produce respiratory depression in patients who have taken other depressant drugs, especially alcohol and barbiturates, or when given rapidly.</li> <li>• If patient received rectal dose prior to EMS arrival, further benzodiazepine administration should be administered with caution.</li> </ul>			
<b>ADMINISTRATION</b>			
IV	<b>Onset:</b> 1–5 minutes	<b>Peak Effect:</b> 15 minutes	<b>Duration:</b> 15–60 minutes
IM	<b>Onset:</b> 15–30 minutes	<b>Peak Effect:</b> 30–45 minutes	<b>Duration:</b> 15–60 minutes
<b>GUIDELINES CONTAINING DIAZEPAM</b>			
<ul style="list-style-type: none"> <li>• <b>Hyperthermia/Heat Exposure: Adult &amp; Pediatric</b></li> </ul>			



DRUG PROFILE		AZDHS	
Diltiazem		5/21/2020	
<b>PHARMACOLOGY &amp; ACTIONS</b>			
<ul style="list-style-type: none"> <li>• Calcium channel blocker.</li> <li>• Inhibitory effects on cardiac conduction system, principally at the AV node, slowing the ventricular rate associated with Atrial Fibrillation and Atrial Flutter.</li> <li>• Inhibits extracellular calcium ion influx across membranes of myocardial cells and vascular smooth muscle cells, resulting in inhibition of contraction and thereby dilating main coronary and systemic arteries.</li> </ul>			
<b>INDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Narrow complex tachyarrhythmias – atrial fibrillation/atrial flutter.</li> <li>• SVT not responding to adenosine.</li> </ul>			
<b>ABSOLUTE CONTRAINDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Heart block/bradycardia.</li> <li>• Systolic blood pressure &lt; 90 mmHg.</li> <li>• Sick sinus syndrome.</li> <li>• Ventricular tachycardia.</li> <li>• Diltiazem allergy.</li> </ul>			
<b>PRECAUTIONS &amp; SIDE EFFECTS</b>			
<ul style="list-style-type: none"> <li>• Prolongation of AV node conduction may result in second- or third-degree AV block.</li> <li>• Should not be administered to compromised myocardium (severe CHF, AMI, or cardiomyopathy).</li> <li>• Use caution when giving to hypotensive patients.</li> </ul>			
<b>ADMINISTRATION</b>			
IV	<b>Onset:</b> 3 minutes	<b>Peak Effect:</b> 7 minutes	<b>Duration:</b> 1–3 hours
<b>GUIDELINES CONTAINING DILTIAZEM</b>			
<ul style="list-style-type: none"> <li>• <b>Tachycardia with a Pulse: Adult &amp; Pediatric</b></li> </ul>			

DRUG PROFILE		AZDHS	
<b>Diphenhydramine</b>		5/21/2020	
<b>PHARMACOLOGY &amp; ACTIONS</b>			
<ul style="list-style-type: none"> <li>• Histamine H1-receptor antagonist (blocks histamine receptors) of effector cells in respiratory tract, blood vessels, and GI smooth muscle.</li> <li>• Also has anticholinergic actions, making it useful in treating or preventing acute dystonic reactions to antipsychotic drugs. These reactions include: oculogyric crisis, acute torticollis, and facial grimacing.</li> </ul>			
<b>INDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Treatment of allergic reactions.</li> <li>• Treatment or prevention of acute dystonic reactions to antipsychotic drugs.</li> </ul>			
<b>ABSOLUTE CONTRAINDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Known hypersensitivity.</li> <li>• Newborns.</li> <li>• Diphenhydramine allergy.</li> </ul>			
<b>PRECAUTIONS &amp; SIDE EFFECTS</b>			
<ul style="list-style-type: none"> <li>• Usually causes sedation, however it may paradoxically cause excitation in children.</li> <li>• May have additive sedation effect with alcohol or other CNS depressants.</li> <li>• May cause hypotension when given IV.</li> </ul>			
<b>ADMINISTRATION</b>			
IV	<b>Onset:</b> 10–15 minutes	<b>Peak Effect:</b> 1 hour	<b>Duration:</b> 6–8 hours
<b>GUIDELINES CONTAINING DIPHENHYDRAMINE</b>			
<ul style="list-style-type: none"> <li>• <b>Anaphylaxis and Allergic Reaction: Adult &amp; Pediatric</b></li> <li>• <b>Poisoning/Overdose Universal Care: Adult &amp; Pediatric</b></li> </ul>			

DRUG PROFILE		AZDHS	
Dopamine (1 of 2 pages)		5/21/2020	
<b>PHARMACOLOGY &amp; ACTIONS</b>			
<ul style="list-style-type: none"> <li>• Endogenous catecholamine.</li> <li>• Acts on both dopaminergic and adrenergic neurons.</li> <li>• Dose dependent effects: <ul style="list-style-type: none"> <li>• 1–2 mcg/kg/min - dilates renal and mesenteric blood vessels, typically no effect on heart rate or blood pressure.</li> <li>• 2–10 mcg/kg/min - beta effects on heart which increases cardiac output without greatly increasing heart rate or blood pressure.</li> <li>• 10–20 mcg/kg/min - alpha peripheral effects causing peripheral vasoconstriction, which results in increase in systemic vascular resistance (SVR) and increased blood pressure.</li> <li>• 20–40 mcg/kg/min - alpha effects reverse dilatation of renal and mesenteric vessels with resultant decreased flow. Increases heart rate and oxygen demand to undesirable limits.</li> </ul> </li> </ul>			
<b>INDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Treatment of refractory cardiogenic or distributive shock.</li> </ul>			
<b>ABSOLUTE CONTRAINDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Hypovolemia.</li> <li>• Dopamine allergy.</li> </ul>			
<b>PRECAUTIONS &amp; SIDE EFFECTS</b>			
<ul style="list-style-type: none"> <li>• May induce tachyarrhythmias, in which case infusion should be decreased or stopped.</li> <li>• High doses (10 mcg/kg) may cause peripheral vasoconstriction.</li> <li>• Should not be added to sodium bicarbonate or other alkaline solutions since dopamine will be inactivated in alkaline solutions.</li> <li>• Consider hypovolemia and treat this with appropriate fluids before administration of dopamine.</li> <li>• Dopamine is best administered by an infusion pump to accurately regulate rate. It may be hazardous when used in the field without an infusion pump. Monitor closely.</li> </ul>			
<b>ADMINISTRATION</b>			
IV	Onset: immediate	Peak Effect: 5–10 minutes	Duration: effects during infusion
<b>PROTOCOLS CONTAINING DOPAMINE</b>			
<ul style="list-style-type: none"> <li>• <b>Shock: Adult &amp; Pediatric</b></li> <li>• <b>Bites and Envenomations: Adult &amp; Pediatric</b></li> </ul>			

DRUG PROFILE

AZDHS

Dopamine (2 of 2 pages)

5/21/2020

**Dopamine Dosage Chart**

800 mg dopamine per 500 mL NS (400 mg dopamine per 250 mL) NS for a concentration of 1600 mcg dopamine per mL. The following table assumes using a 60 drops per mL (microdrop) infusion set.

**DOPAMINE TABLE**

PT WEIGHT		DESIRED DOSE (drops/min)		
Lbs	Kg	5 mcg/kg/min	10 mcg/kg/min	20 mcg/kg/min
88	40	8	15	30
100	45	8	17	34
110	50	9	19	38
120	55	10	21	41
132	60	11	23	45
143	65	12	24	49
154	70	13	26	53
165	75	14	28	56
176	80	15	30	60
187	85	16	32	64
198	90	17	34	68
209	95	18	36	71
220	100	19	38	75
231	105	20	39	79
242	110	21	41	83
253	115	22	43	86
264	120	23	45	90
275	125	23	47	94
286	130	24	49	98
297	135	25	51	102
308	140	26	53	106

**USING THE DOPAMINE TABLE:**

Find patient weight and then move across row to the column for the desired dose. Set dial-a-flow to the corresponding flow rate.

DRUG PROFILE		AZDHS	
Epinephrine		5/21/2020	
<b>PHARMACOLOGY &amp; ACTIONS</b>			
<ul style="list-style-type: none"> <li>• Catecholamine with alpha and beta effects which increases heart rate and blood pressure.</li> <li>• Potent bronchodilator.</li> </ul>			
<b>INDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Cardiac Arrest.</li> <li>• Bradycardia.</li> <li>• Anaphylaxis.</li> <li>• Shock.</li> <li>• IM for severe refractory wheezing.</li> <li>• Nebulized for croup and bronchiolitis.</li> </ul>			
<b>ABSOLUTE CONTRAINDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Uncontrolled hypertension is a relative contraindication.</li> <li>• Epinephrine allergy.</li> </ul>			
<b>PRECAUTIONS &amp; SIDE EFFECTS</b>			
<ul style="list-style-type: none"> <li>• Epinephrine increases cardiac work and can precipitate angina, myocardial infarction or major dysrhythmias in an individual with ischemic heart disease.</li> </ul>			
<b>ADMINISTRATION</b>			
IV	<b>Onset:</b> < 2 minutes	<b>Peak Effect:</b> < 5 minutes	<b>Duration:</b> 5–10 minutes
IM	<b>Onset:</b> 3–10 minutes	<b>Peak Effect:</b> 20 minutes	<b>Duration:</b> 20–30 minutes
<b>GUIDELINES CONTAINING EPINEPHRINE</b>			
<ul style="list-style-type: none"> <li>• <b>Bradycardia: Adult &amp; Pediatric</b></li> <li>• <b>Bronchospasm (due to Asthma and Obstructive Lung Disease): Adult &amp; Pediatric</b></li> <li>• <b>Anaphylaxis and Allergic Reaction: Adult &amp; Pediatric</b></li> <li>• <b>Shock: Adult &amp; Pediatric</b></li> <li>• <b>Cardiac Arrest (VF/VT/Asystole/PEA): Age 8 and Older</b></li> <li>• <b>Cardiac Arrest (VF/VT/Asystole/PEA): Pediatric Age &lt; 8</b></li> <li>• <b>Pediatric Respiratory Distress – Wheezing &lt; 2 Years Old (Bronchiolitis)</b></li> <li>• <b>Pediatric Stridor (e.g., Croup)</b></li> <li>• <b>Neonatal Resuscitation page 1 of 2</b></li> <li>• <b>Neonatal Resuscitation page 2 of 2</b></li> <li>• <b>Bites and Envenomations: Adult &amp; Pediatric</b></li> </ul>			

DRUG PROFILE		AZDHS	
Etomidate		5/21/2020	
<b>PHARMACOLOGY &amp; ACTIONS</b>			
<ul style="list-style-type: none"> <li>• Sedative and hypnotic.</li> <li>• Appears to act similar to GABA by depressing the activity of the brain stem reticular activating system.</li> <li>• No analgesic properties.</li> </ul>			
<b>INDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Induction of anesthesia for rapid sequence intubation.</li> </ul>			
<b>ABSOLUTE CONTRAINDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Known hypersensitivity.</li> <li>• Etomidate allergy.</li> </ul>			
<b>PRECAUTIONS &amp; SIDE EFFECTS</b>			
<ul style="list-style-type: none"> <li>• Not intended for prolonged infusion due to suppression of cortisol and aldosterone production.</li> </ul>			
<b>ADMINISTRATION</b>			
IV	<b>Onset:</b> 10–20 seconds	<b>Peak Effect:</b> < 1 minute	<b>Duration:</b> 3–5 minutes
<b>GUIDELINES CONTAINING ETOMIDATE</b>			
None.			

DRUG PROFILE		AZDHS	
Fentanyl		5/21/2020	
<b>PHARMACOLOGY &amp; ACTIONS</b>			
<ul style="list-style-type: none"> <li>• Opioid agonist-analgesic.</li> <li>• Inhibits ascending pain pathways, thus altering response to pain, increases pain threshold.</li> <li>• Produces analgesia, respiratory depression, and sedation.</li> </ul>			
<b>INDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Severe pain of any etiology.</li> </ul>			
<b>ABSOLUTE CONTRAINDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Oxygen saturation less than 90% or significant respiratory depression.</li> <li>• Fentanyl allergy.</li> </ul>			
<b>PRECAUTIONS &amp; SIDE EFFECTS</b>			
<ul style="list-style-type: none"> <li>• Fentanyl causes neurologic and respiratory depression. Respiratory depression may be worse in patients with underlying lung disease or concomitant use of other depressant drugs such as benzodiazepines or alcohol. Respiratory support must be available when administering fentanyl.</li> <li>• Fentanyl can be reversed with naloxone.</li> <li>• When fentanyl is given to treat pain, the goal is reduction of pain not total elimination of pain.</li> </ul>			
<b>ADMINISTRATION</b>			
IV	<b>Onset:</b> immediate	<b>Peak Effect:</b> 3–5 minutes	<b>Duration:</b> 30–60 minutes
<b>GUIDELINES CONTAINING FENTANYL</b>			
<ul style="list-style-type: none"> <li>• <b>Management of Acute Pain: Adult &amp; Pediatric</b></li> <li>• <b>Chest Pain/Acute Coronary Syndrome/ST-segment Elevation Myocardial Infarction (STEMI): Adult</b></li> </ul>			

DRUG PROFILE		AZDHS	
Glucagon		5/21/2020	
<b>PHARMACOLOGY &amp; ACTIONS</b>			
<ul style="list-style-type: none"><li>Increases serum glucose by releasing glycogen stores from the liver.</li><li>Glucagon will only work if there are sufficient stores of glycogen in the liver, and will not work if patient is malnourished.</li><li>Counteracts effects of beta blocker or calcium channel blocker overdose.</li></ul>			
<b>INDICATIONS</b>			
<ul style="list-style-type: none"><li>Hypoglycemia.</li><li>Symptomatic bradycardia from beta blocker or calcium channel blocker overdose.</li></ul>			
<b>ABSOLUTE CONTRAINDICATIONS</b>			
<ul style="list-style-type: none"><li>Glucagon is not the first line treatment for hypoglycemia and should ONLY be used in patient with symptomatic hypoglycemia when the EMCT is unable to obtain IV access.</li><li>Glucagon allergy.</li></ul>			
<b>PRECAUTIONS &amp; SIDE EFFECTS</b>			
<ul style="list-style-type: none"><li>May cause nausea and vomiting.</li><li>Slower onset than IV dextrose.</li></ul>			
<b>ADMINISTRATION</b>			
IM	Onset: 5–20 minutes	Peak Effect: 30 minutes	Duration: 1–2 hours
<b>GUIDELINES CONTAINING GLUCAGON</b>			
<ul style="list-style-type: none"><li>Hypoglycemia: Adult &amp; Pediatric</li></ul>			



DRUG PROFILE		AZDHS	
Glucose, oral		5/21/2020	
<b>PHARMACOLOGY &amp; ACTIONS</b>			
<ul style="list-style-type: none"> <li>• Monosaccharide carbohydrate.</li> <li>• After absorption from GI tract, glucose is distributed in the tissues and provides a prompt increase in circulating blood sugar.</li> </ul>			
<b>INDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Hypoglycemia.</li> </ul>			
<b>ABSOLUTE CONTRAINDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Glucose allergy.</li> </ul>			
<b>PRECAUTIONS &amp; SIDE EFFECTS</b>			
<ul style="list-style-type: none"> <li>• Altered level of consciousness.</li> <li>• Ascertain the patient's ability to swallow an oral preparation of glucose without airway compromise.</li> <li>• Must be swallowed, not absorbed sublingually or buccally.</li> </ul>			
<b>ADMINISTRATION</b>			
PO	<b>Onset:</b> 10 minutes	<b>Peak Effect:</b> variable	<b>Duration:</b> variable
<b>GUIDELINESS CONTAINING GLUCOSE</b>			
<ul style="list-style-type: none"> <li>• <b>Hypoglycemia: Adult &amp; Pediatric</b></li> </ul>			

DRUG PROFILE		AZDHS	
<b>Hydroxocobalamin (Cyanokit)</b>		5/21/2020	
<b>PHARMACOLOGY &amp; ACTIONS</b>			
<ul style="list-style-type: none"> <li>• Precursor to Vitamin B12.</li> <li>• Hydroxocobalamin binds cyanide ions to form Cyanocobalamin (vitamin B12) which is then excreted in the urine.</li> </ul>			
<b>INDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Known or suspected cyanide poisoning.</li> <li>• Closed-space smoke inhalation exposure with: <ul style="list-style-type: none"> <li>• Shock</li> <li>• Cardiac arrest</li> <li>• Altered level of consciousness</li> </ul> </li> </ul>			
<b>ABSOLUTE CONTRAINDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Hydroxocobalamin allergy.</li> </ul>			
<b>PRECAUTIONS &amp; SIDE EFFECTS</b>			
<ul style="list-style-type: none"> <li>• May cause transient elevation of blood pressure.</li> <li>• Will cause red colored urine (for up to 5 weeks) and red colored skin (for up to 2 weeks). The red color of the blood serum and urine will interfere with colorimetric laboratory tests for several days.</li> </ul>			
<b>ADMINISTRATION</b>			
IV	<b>Onset:</b> 2–15 minutes	<b>Peak Effect:</b> variable	<b>Duration:</b> variable
<b>GUIDELINES CONTAINING HYDROXOCOBALAMIN (CYANOKIT)</b>			
<ul style="list-style-type: none"> <li>• <b>Suspected Cyanide Poisoning: Adult &amp; Pediatric</b></li> </ul>			

DRUG PROFILE		AZDHS	
<b>Ipratropium Bromide</b>		5/21/2020	
<b>PHARMACOLOGY &amp; ACTIONS</b>			
<ul style="list-style-type: none"><li>• Antagonizes action of acetylcholine on the bronchial smooth muscle in the lungs, causing bronchodilation.</li></ul>			
<b>INDICATIONS</b>			
<ul style="list-style-type: none"><li>• Bronchoconstriction – asthma and COPD.</li><li>• Ipratropium may be given in a combination with albuterol anytime albuterol is indicated.</li></ul>			
<b>ABSOLUTE CONTRAINDICATIONS</b>			
<ul style="list-style-type: none"><li>• Ipratropium bromide allergy.</li></ul>			
<b>PRECAUTIONS &amp; SIDE EFFECTS</b>			
<ul style="list-style-type: none"><li>• Use with caution in patients with narrow angle glaucoma.</li><li>• Side effects may include palpitations, dizziness, anxiety, headache, eye pain, urinary retention, and anxiety.</li></ul>			
<b>ADMINISTRATION</b>			
SVN	<b>Onset:</b> 5–15 minutes	<b>Peak Effect:</b> 1.5–2 hours	<b>Duration:</b> 4–6 hours
<b>GUIDELINES CONTAINING IPRATROPIUM</b>			
<ul style="list-style-type: none"><li>• <b>Bronchospasm (due to Asthma and Obstructive Lung Disease): Adult &amp; Pediatric</b></li></ul>			

DRUG PROFILE		AZDHS	
Ketamine		5/21/2020	
<b>PHARMACOLOGY &amp; ACTIONS</b>			
<ul style="list-style-type: none"> <li>• Ketamine is a non-competitive NMDA receptor antagonist.</li> <li>• It functions as a dissociative, amnestic, analgesic, and anesthetic agent.</li> </ul>			
<b>INDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Delirium with agitated behavior.</li> <li>• Induction agent for intubation.</li> <li>• Pain control.</li> </ul>			
<b>ABSOLUTE CONTRAINDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Angina.</li> <li>• CHF.</li> <li>• Pregnancy.</li> <li>• Ketamine allergy.</li> </ul>			
<b>PRECAUTIONS &amp; SIDE EFFECTS</b>			
<ul style="list-style-type: none"> <li>• Transient periods of apnea (1-2 minutes) have occurred with IV ketamine administration, especially with rapid infusion.</li> <li>• May cause laryngospasm.</li> <li>• May cause hypersalivation, increased airway secretions.</li> <li>• May cause emergence reaction.</li> <li>• May cause nystagmus.</li> <li>• Use with caution in patients with schizophrenia.</li> </ul>			
<b>ADMINISTRATION</b>			
IV	<b>Onset:</b> < 1 minute	<b>Peak Effect:</b> 30 seconds – 5 minutes	<b>Duration:</b> 10–45 minutes
IM	<b>Onset:</b> 3–4 minutes	<b>Peak Effect:</b> 3–12 minutes	<b>Duration:</b> 25–60 minutes
<b>GUIDELINES CONTAINING KETAMINE</b>			
<ul style="list-style-type: none"> <li>• <b>Agitated or Violent Patient/Behavioral Emergency: Adult &amp; Pediatric</b></li> <li>• <b>Management of Acute Pain: Adult &amp; Pediatric</b></li> </ul>			

DRUG PROFILE		AZDHS	
Lidocaine		5/21/2020	
<b>PHARMACOLOGY &amp; ACTIONS</b>			
<ul style="list-style-type: none"> <li>• Antiarrhythmic drug that decreases automaticity by slowing the rate of depolarization.</li> <li>• Terminates re-entry by decreasing conduction in re-entrant pathways.</li> <li>• Local anesthesia for pain control caused by infusion of fluids or medications via an intraosseous (IO) site.</li> </ul>			
<b>INDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Cardiac Arrest due to Ventricular Fibrillation or Pulseless Ventricular Tachycardia.</li> <li>• Wide complex tachycardia with a pulse.</li> <li>• Pain management after IO insertion in conscious patients.</li> </ul>			
<b>ABSOLUTE CONTRAINDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Bradycardia.</li> <li>• Lidocaine allergy.</li> </ul>			
<b>PRECAUTIONS &amp; SIDE EFFECTS</b>			
<ul style="list-style-type: none"> <li>• At higher doses may cause CNS stimulation, seizure, depression, and respiratory failure.</li> <li>• Toxicity is more likely in elderly patients and patients with Congestive Heart Failure or impaired liver function.</li> </ul>			
<b>ADMINISTRATION</b>			
IV	Onset: < 3 minutes	Peak Effect: 5–10 minutes	Duration: 10–20 minutes
<b>GUIDELINES CONTAINING LIDOCAINE</b>			
<ul style="list-style-type: none"> <li>• <b>Tachycardia with a Pulse: Adult &amp; Pediatric</b></li> <li>• <b>Cardiac Arrest (VF/VT/Asystole/PEA): Age 8 and Older</b></li> <li>• <b>Cardiac Arrest (VF/VT/Asystole/PEA): Pediatric Age &lt; 8</b></li> </ul>			

DRUG PROFILE		AZDHS	
Lorazepam		5/21/2020	
<b>PHARMACOLOGY &amp; ACTIONS</b>			
<ul style="list-style-type: none"> <li>Benzodiazepine that functions as a CNS depressant, anticonvulsant, and sedative.</li> </ul>			
<b>INDICATIONS</b>			
<ul style="list-style-type: none"> <li>Seizures.</li> <li>Sedation.</li> <li>Agitation/delirium with agitated behavior.</li> <li>Uncontrolled shivering in hyperthermia.</li> </ul>			
<b>ABSOLUTE CONTRAINDICATIONS</b>			
<ul style="list-style-type: none"> <li>Neurologic or respiratory depression.</li> <li>Acute angle glaucoma.</li> <li>Lorazepam allergy.</li> </ul>			
<b>PRECAUTIONS &amp; SIDE EFFECTS</b>			
<ul style="list-style-type: none"> <li>Respiratory depression and/or hypotension can occur, the patient should be monitored closely.</li> <li>Most likely to produce respiratory depression in patients who have taken other depressant drugs, especially alcohol and barbiturates, or when given rapidly.</li> <li>Elderly patients may have more profound respiratory and/or CNS depression, half dose should be administered.</li> </ul>			
<b>ADMINISTRATION</b>			
IV	<b>Onset:</b> 1–2 minutes	<b>Peak Effect:</b> < 15 minutes	<b>Duration:</b> 6–8 hours
IM	<b>Onset:</b> 15–30 minutes	<b>Peak Effect:</b> 2–3 hours	<b>Duration:</b> 6–8 hours
<b>GUIDELINES CONTAINING LORAZEPAM</b>			
<ul style="list-style-type: none"> <li><b>Agitated or Violent Patient/Behavioral Emergency: Adult &amp; Pediatric</b></li> <li><b>Bradycardia: Adult &amp; Pediatric</b></li> <li><b>Seizures: Adult &amp; Pediatric</b></li> <li><b>Hyperthermia/Heat Exposure: Adult &amp; Pediatric</b></li> </ul>			

DRUG PROFILE		AZDHS	
<b>Magnesium Sulfate</b>		5/21/2020	
<b>PHARMACOLOGY &amp; ACTIONS</b>			
<ul style="list-style-type: none"> <li>• Smooth muscle relaxant.</li> <li>• Decreases early after depolarizations and reduces arrhythmias.</li> <li>• Decreases seizures in eclampsia and preeclampsia, possibly via cerebral vasodilation.</li> <li>• CNS depressant.</li> </ul>			
<b>INDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Eclampsia and preeclampsia.</li> <li>• Torsades de pointes.</li> <li>• Severe bronchospasm in patients with asthma or COPD.</li> </ul>			
<b>ABSOLUTE CONTRAINDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Magnesium allergy.</li> </ul>			
<b>PRECAUTIONS &amp; SIDE EFFECTS</b>			
<ul style="list-style-type: none"> <li>• May cause hypotension and respiratory depression in large doses.</li> <li>• Caution with use in patients with renal insufficiency or chronic renal failure/dialysis.</li> </ul>			
<b>ADMINISTRATION</b>			
IV	Onset: immediate	Peak Effect: variable	Duration: 1 hour
<b>GUIDELINESS CONTAINING MAGNESIUM SULFATE</b>			
<ul style="list-style-type: none"> <li>• <b>Tachycardia with a Pulse: Adult &amp; Pediatric</b></li> <li>• <b>Bronchospasm (due to Asthma and Obstructive Lung Disease): Adult &amp; Pediatric</b></li> <li>• <b>Seizures: Adult &amp; Pediatric</b></li> <li>• <b>Cardiac Arrest (VF/VT/Asystole/PEA): Age 8 and Older</b></li> <li>• <b>Cardiac Arrest (VF/VT/Asystole/PEA): Pediatric Age &lt; 8</b></li> <li>• <b>Childbirth</b></li> <li>• <b>Obstetrical/Gynecological Conditions</b></li> </ul>			

DRUG PROFILE		AZDHS	
<b>Methylene blue</b>		01/20/2022	
<b>PHARMACOLOGY &amp; ACTIONS</b>			
<ul style="list-style-type: none"> <li>Used in the treatment of methemoglobin (MetHgb) toxicity. Converts MetHgb back to normal hemoglobin and reverses hypoxia. Acts as reducing agent to convert iron in methemoglobin from Fe<sup>3+</sup> to Fe<sup>2+</sup> regenerating normal hemoglobin.</li> </ul>			
<b>INDICATIONS</b>			
<ul style="list-style-type: none"> <li>Treatment of symptomatic methemoglobinemia.</li> </ul>			
<b>ABSOLUTE CONTRAINDICATIONS</b>			
<ul style="list-style-type: none"> <li>Known glucose-6-phosphate dehydrogenase (G6PD) deficiency.</li> <li>Hemolysis or history of hemolytic anemia.</li> </ul>			
<b>PRECAUTIONS &amp; SIDE EFFECTS</b>			
<ul style="list-style-type: none"> <li>Side effects: Chest pain, vomiting, flushing, confusion and headache.</li> <li>Pulse oximetry will be transiently unreliable (very low) immediately after administration.</li> </ul>			
<b>ADMINISTRATION</b>			
IV/IO	<b>Onset:</b> Within 1-2 minutes.	<b>Peak Effect:</b> 30 minutes.	<b>Duration:</b> 30-60 minutes.
<b>GUIDELINES CONTAINING METHYLENE BLUE</b>			
<ul style="list-style-type: none"> <li>Methemoglobin Toxicity: Adult &amp; Pediatric</li> </ul>			



DRUG PROFILE		AZDHS	
<b>Methylprednisolone Sodium Succinate</b>		5/21/2020	
<b>PHARMACOLOGY &amp; ACTIONS</b>			
<ul style="list-style-type: none"> <li>• Potent synthetic steroid that inhibits many substances that cause inflammatory response.</li> <li>• Controls or prevents inflammation by controlling rate of protein synthesis, suppressing migration of polymorphonuclear leukocytes (PMNs) and fibroblasts, reversing capillary permeability, and stabilizing lysosomes at cellular level.</li> </ul>			
<b>INDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Acute bronchospastic disease (asthma or COPD).</li> <li>• Adrenal Insufficiency.</li> </ul>			
<b>ABSOLUTE CONTRAINDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Traumatic brain injury (high doses).</li> <li>• Methylprednisolone sodium succinate allergy.</li> </ul>			
<b>PRECAUTIONS &amp; SIDE EFFECTS</b>			
<b>ADMINISTRATION</b>			
IV	Onset: 1–6 hours	Peak Effect: 8 hours	Duration: 18–36 hours
<b>GUIDELINES CONTAINING METHYLPREDNISOLONE SODIUM SUCCINATE</b>			
<ul style="list-style-type: none"> <li>• <b>Bronchospasm (due to Asthma and Obstructive Lung Disease): Adult &amp; Pediatric</b></li> <li>• <b>Shock: Adult &amp; Pediatric</b></li> </ul>			

DRUG PROFILE		AZDHS	
Midazolam		5/21/2020	
<b>PHARMACOLOGY &amp; ACTIONS</b>			
<ul style="list-style-type: none"> <li>Benzodiazepine that functions as a CNS depressant, anticonvulsant, and sedative.</li> </ul>			
<b>INDICATIONS</b>			
<ul style="list-style-type: none"> <li>Seizures.</li> <li>Sedation.</li> <li>Agitation/delirium with agitated behavior.</li> <li>Uncontrolled shivering in hyperthermia.</li> </ul>			
<b>ABSOLUTE CONTRAINDICATIONS</b>			
<ul style="list-style-type: none"> <li>Respiratory and/or CNS depression.</li> <li>Midazolam allergy.</li> </ul>			
<b>PRECAUTIONS &amp; SIDE EFFECTS</b>			
<ul style="list-style-type: none"> <li>Midazolam has more potential than the other IV benzodiazepines to cause respiratory depression. Respiratory depression and/or hypotension can occur, the patient should be monitored closely.</li> <li>Most likely to produce respiratory depression in patients who have taken other depressant drugs, especially alcohol and barbiturates, or when given rapidly.</li> <li>Elderly patients may have more profound respiratory and/or CNS depression, half dose should be administered.</li> </ul>			
<b>ADMINISTRATION</b>			
IV/IN	<b>Onset:</b> immediate	<b>Peak Effect:</b> 3–5 minutes	<b>Duration:</b> < 2 hours
IM	<b>Onset:</b> 15 minutes	<b>Peak Effect:</b> 30–60 minutes	<b>Duration:</b> 1–6 hours
<b>GUIDELINES CONTAINING MIDAZOLAM</b>			
<ul style="list-style-type: none"> <li><b>Hyperthermia/Heat Exposure: Adult &amp; Pediatric</b></li> <li><b>Agitated or Violent Patient/Behavioral Emergency: Adult &amp; Pediatric</b></li> <li><b>Bradycardia: Adult &amp; Pediatric</b></li> <li><b>Seizures: Adult &amp; Pediatric</b></li> </ul>			

DRUG PROFILE		AZDHS	
<b>Morphine Sulfate</b>		5/21/2020	
<b>PHARMACOLOGY &amp; ACTIONS</b>			
<ul style="list-style-type: none"> <li>• Narcotic analgesic.</li> <li>• Alleviates pain by acting on the pain receptors in the brain, elevates pain threshold.</li> <li>• CNS depressant, depresses brainstem respiratory centers.</li> <li>• Increases venous pooling, vasodilates arterioles, reducing preload and afterload.</li> <li>• Histamine release.</li> </ul>			
<b>INDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Analgesia.</li> </ul>			
<b>ABSOLUTE CONTRAINDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Respiratory and/or CNS depression.</li> <li>• Hypotension.</li> <li>• Morphine sulfate allergy.</li> </ul>			
<b>PRECAUTIONS &amp; SIDE EFFECTS</b>			
<ul style="list-style-type: none"> <li>• Morphine causes neurologic and respiratory depression. Respiratory depression may be worse in patients with underlying lung disease or concomitant use of other depressant drugs such as benzodiazepines or alcohol.</li> <li>• Morphine can be reversed with naloxone.</li> <li>• Check and document vital signs and patient response after each dose.</li> <li>• When morphine is given to treat pain, the goal is reduction of pain not total elimination of pain.</li> </ul>			
<b>ADMINISTRATION</b>			
IV	<b>Onset:</b> seconds	<b>Peak Effect:</b> 20 minutes	<b>Duration:</b> 2–4 hours
<b>GUIDELINES CONTAINING MORPHINE SULFATE</b>			
<ul style="list-style-type: none"> <li>• <b>Management of Acute Pain: Adult &amp; Pediatric</b></li> <li>• <b>Chest Pain/Acute Coronary Syndrome/ST-segment Elevation Myocardial Infarction (STEMI): Adult</b></li> </ul>			

DRUG PROFILE		AZDHS	
Naloxone		5/21/2020	
<b>PHARMACOLOGY &amp; ACTIONS</b>			
<ul style="list-style-type: none"> <li>Naloxone is a narcotic antagonist which competitively binds to opioid receptors in the brain.</li> <li>Displaces opioid molecules, reversing the effect of opioids on the brain.</li> </ul>			
<b>INDICATIONS</b>			
<ul style="list-style-type: none"> <li>Reversal of acute opioid toxicity.</li> </ul>			
<b>ABSOLUTE CONTRAINDICATIONS</b>			
<ul style="list-style-type: none"> <li>Naloxone allergy.</li> </ul>			
<b>PRECAUTIONS &amp; SIDE EFFECTS</b>			
<ul style="list-style-type: none"> <li>May precipitate acute withdrawal symptoms in patients who chronically use opioids.</li> <li>Agitation, tachycardia, pulmonary edema, nausea, vomiting, and seizures (in neonates.)</li> <li>Be prepared to restrain the patient as they may become violent with reverse of the narcotic effect.</li> <li>The duration of some narcotics is longer than Naloxone.</li> <li>Repeated doses of Naloxone may be required for some opioid toxicities.</li> </ul>			
<b>ADMINISTRATION</b>			
IV	<b>Onset:</b> < 2 minutes	<b>Peak Effect:</b> < 2 minutes	<b>Duration:</b> 20–120 minutes
IM/IN	<b>Onset:</b> 2–10 minutes	<b>Peak Effect:</b> 2–10 minutes	<b>Duration:</b> 20–120 minutes
<b>GUIDELINES CONTAINING NALOXONE</b>			
<ul style="list-style-type: none"> <li><b>Altered Mental Status: Adult &amp; Pediatric</b></li> <li><b>Opioid Poisoning/Overdose: Adult &amp; Pediatric</b></li> </ul>			

DRUG PROFILE		AZDHS	
Nitroglycerin		5/21/2020	
<b>PHARMACOLOGY &amp; ACTIONS</b>			
<ul style="list-style-type: none"> <li>• Potent smooth muscle relaxant.</li> <li>• Causes systemic venodilation, decreasing preload.</li> <li>• Arterial vasodilation, decreasing afterload.</li> <li>• Coronary artery vasodilation.</li> <li>• Increases blood flow to the myocardium.</li> <li>• Decreases myocardial oxygen demand.</li> </ul>			
<b>INDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Chest pain, particularly when Acute Coronary Syndrome is suspected.</li> <li>• Hypertensive Emergency.</li> <li>• Congestive Heart Failure with pulmonary edema.</li> </ul>			
<b>ABSOLUTE CONTRAINDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Hypotension.</li> <li>• Recent use of erectile dysfunction medications (48 hours).</li> <li>• Nitroglycerin is <b>not to be given</b> to children in the prehospital setting.</li> <li>• Nitroglycerin allergy.</li> </ul>			
<b>PRECAUTIONS &amp; SIDE EFFECTS</b>			
<ul style="list-style-type: none"> <li>• Generalized vasodilatation may cause profound hypotension and reflex tachycardia.</li> <li>• May cause profound hypotension in patients taking medication for erectile dysfunction.</li> <li>• Common side effects include throbbing headache, flushing, dizziness and burning under the tongue.</li> <li>• Because nitroglycerin causes generalized smooth muscle relaxation, it may be effective in relieving chest pain caused by esophageal spasm.</li> </ul>			
<b>ADMINISTRATION</b>			
SL	<b>Onset:</b> immediate	<b>Peak Effect:</b> 5-10 minutes	<b>Duration:</b> 20-30 minutes
<b>GUIDELINES CONTAINING NITROGLYCERIN</b>			
<ul style="list-style-type: none"> <li>• <b>Chest Pain/Acute Coronary Syndrome/ST-segment Elevation Myocardial Infarction (STEMI): Adult</b></li> <li>• <b>Pulmonary Edema: Adult &amp; Pediatric</b></li> </ul>			

DRUG PROFILE		AZDHS	
<b>Norepinephrine (Infusion Pump Only)</b>		5/21/2020	
<b>PHARMACOLOGY &amp; ACTIONS</b>			
<ul style="list-style-type: none"> <li>• Catecholamine that stimulates beta-1 and alpha-1 receptors in the sympathetic nervous system.</li> <li>• Results in vasoconstriction, increased blood pressure, enhanced contractility, and increased heart rate.</li> </ul>			
<b>INDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Hypotension unresponsive to IV fluid resuscitation.</li> </ul>			
<b>ABSOLUTE CONTRAINDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Hypotension caused by hypovolemia (blood volume deficit).</li> <li>• Norepinephrine allergy.</li> </ul>			
<b>PRECAUTIONS &amp; SIDE EFFECTS</b>			
<ul style="list-style-type: none"> <li>• Ensure adequate fluid replacement before starting norepinephrine.</li> <li>• Administer through largest vein possible to reduce risk of tissue necrosis if it extravasates.</li> <li>• Monitor blood pressure closely.</li> <li>• Must be administered via infusion pump.</li> </ul>			
<b>ADMINISTRATION</b>			
IV (infusion pump only)	<b>Onset:</b> immediate	<b>Peak Effect:</b> < 1 minute	<b>Duration:</b> 1–2 minutes
<b>GUIDELINES CONTAINING NOREPINEPHRINE</b>			
<ul style="list-style-type: none"> <li>• <b>Shock: Adult &amp; Pediatric</b></li> <li>• <b>Bites and Envenomations: Adult &amp; Pediatric</b></li> </ul>			

DRUG PROFILE		AZDHS	
Ondansetron		5/21/2020	
<b>PHARMACOLOGY &amp; ACTIONS</b>			
<ul style="list-style-type: none"> <li>• Selectively blocks serotonin 5-HT<sub>3</sub> receptors in the brain.</li> <li>• Primary effect is in the GI tract.</li> <li>• No effect on dopamine receptors and therefore does not cause extrapyramidal symptoms.</li> </ul>			
<b>INDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Nausea or vomiting.</li> </ul>			
<b>ABSOLUTE CONTRAINDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Patients with prolonged QT.</li> <li>• Patients &lt; 1 month old.</li> <li>• Ondansetron allergy.</li> </ul>			
<b>PRECAUTIONS &amp; SIDE EFFECTS</b>			
<ul style="list-style-type: none"> <li>• May cause QT prolongation, avoid use in patients with prolonged QT syndrome.</li> </ul>			
<b>ADMINISTRATION</b>			
IV/PO/SL	<b>Onset:</b> 10–30 minutes	<b>Peak Effect:</b> 1.5 hours	<b>Duration:</b> 8 hours
<b>GUIDELINES CONTAINING ONDANSETRON</b>			
<ul style="list-style-type: none"> <li>• <b>Nausea/Vomiting: Adult &amp; Pediatric</b></li> </ul>			

DRUG PROFILE		AZDHS	
<b>Oxytocin</b>		5/21/2020	
<b>PHARMACOLOGY &amp; ACTIONS</b>			
<ul style="list-style-type: none"> <li>• Binds to oxytocin receptor sites on surface of uterine smooth muscles.</li> <li>• Increases force and frequency of uterine contractions.</li> </ul>			
<b>INDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Postpartum hemorrhage due to uterine atony.</li> </ul>			
<b>ABSOLUTE CONTRAINDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Known hypersensitivity.</li> <li>• Oxytocin allergy.</li> </ul>			
<b>PRECAUTIONS &amp; SIDE EFFECTS</b>			
<ul style="list-style-type: none"> <li>• Shock, tachycardia, dysrhythmias.</li> <li>• Anaphylaxis.</li> <li>• Nausea and vomiting.</li> <li>• If used prior to delivery, can cause uterine rupture, uterine spasm, lacerations, and fetal damage.</li> <li>• Clotting disorders, electrolyte disturbances.</li> </ul>			
<b>ADMINISTRATION</b>			
IV/IM	<b>Onset:</b> seconds	<b>Peak Effect:</b> variable	<b>Duration:</b> 1 hour after discontinued
<b>GUIDELINES CONTAINING OXYTOCIN</b>			
None.			



DRUG PROFILE		AZDHS	
Phenylephrine Nasal Spray 0.5%		5/21/2020	
<b>PHARMACOLOGY &amp; ACTIONS</b>			
<ul style="list-style-type: none"><li>Stimulates alpha receptors in the blood vessels of the nasal mucosa which causes their constriction and thereby decreases the risk of nasal bleeding.</li></ul>			
<b>INDICATIONS</b>			
<ul style="list-style-type: none"><li>Facilitation of nasotracheal intubation.</li><li>Epistaxis.</li></ul>			
<b>ABSOLUTE CONTRAINDICATIONS</b>			
<ul style="list-style-type: none"><li>Phenylephrine allergy.</li></ul>			
<b>PRECAUTIONS &amp; SIDE EFFECTS</b>			
<ul style="list-style-type: none"><li>Each bottle is single patient use only.</li><li>Hypertension, palpitations.</li><li>Tremors.</li></ul>			
<b>ADMINISTRATION</b>			
IN	Onset: seconds	Peak Effect: 30 minutes	Duration: 30 minutes–4 hours
<b>GUIDELINES CONTAINING PHENYLEPHRINE NASAL SPRAY</b>			
None.			

DRUG PROFILE		AZDHS	
<b>Pralidoxime Autoinjector</b>		5/21/2020	
<b>PHARMACOLOGY &amp; ACTIONS</b>			
<ul style="list-style-type: none"><li>• Binds to organophosphates and breaks alkyl phosphate-cholinesterase bond (removes phosphate group from cholinesterase) to restore activity of acetylcholinesterase.</li><li>• Must be administered before the alkyl phosphate-cholinesterase bond becomes permanent (this is referred to as aging).</li></ul>			
<b>INDICATIONS</b>			
<ul style="list-style-type: none"><li>• Poisoning by organophosphate insecticides and related nerve gases (e.g., tabun, sarin, soman).</li></ul>			
<b>ABSOLUTE CONTRAINDICATIONS</b>			
<ul style="list-style-type: none"><li>• Pralidoxime allergy.</li></ul>			
<b>PRECAUTIONS &amp; SIDE EFFECTS</b>			
<ul style="list-style-type: none"><li>• Rapid injection may cause laryngospasm, tachycardia, and muscle rigidity - intubation may be required.</li><li>• Speeds the effect of atropine when used together.</li><li>• Excitement and manic behavior can occur immediately after recovery from unconsciousness.</li></ul>			
<b>ADMINISTRATION</b>			
IM	<b>Onset:</b> variable	<b>Peak Effect:</b> 10–20 minutes	<b>Duration:</b> variable
<b>GUIDELINES CONTAINING PRALIDOXIME</b>			
None.			

DRUG PROFILE		AZDHS	
Proparacaine Ophthalmic		5/21/2020	
<b>PHARMACOLOGY &amp; ACTIONS</b>			
<ul style="list-style-type: none"> <li>• Site of action is at the ophthalmic pain nerve cell membrane.</li> <li>• Alleviates pain by limiting the sodium ion permeability in these nerve cell membranes; this elevates the threshold stimulus needed to trigger action potential in these cells. When the action is sufficiently well developed, block of conduction is produced.</li> </ul>			
<b>INDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Induction of topical anesthesia prior to irrigation of eyes with or without adjuncts, e.g., Morgan's lens.</li> </ul>			
<b>ABSOLUTE CONTRAINDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Known hypersensitivity.</li> <li>• Proparacaine allergy.</li> </ul>			
<b>PRECAUTIONS &amp; SIDE EFFECTS</b>			
<ul style="list-style-type: none"> <li>• Each bottle is single patient use only.</li> <li>• Pupillary dilation, local irritation, softening and erosion of cornea (rare). Severe hyperallergic corneal reaction with corneal sloughing (extremely rare).</li> <li>• Allergic dermatitis conjunctiva and eyelids (rare).</li> </ul>			
<b>ADMINISTRATION</b>			
Eye Drops	<b>Onset:</b> 30–120 seconds	<b>Peak Effect:</b> 30–120 seconds	<b>Duration:</b> 5–10 minutes
<b>GUIDELINES CONTAINING PROPARACAINE HYDROCHLORIDE OPHTHALMIC</b>			
<ul style="list-style-type: none"> <li>• <b>Dermal Chemical Burns: Adult &amp; Pediatric</b></li> </ul>			

DRUG PROFILE		AZDHS	
<b>Propranolol</b>		01/20/2022	
<b>PHARMACOLOGY &amp; ACTIONS</b>			
<ul style="list-style-type: none"> <li>Propranolol is a nonselective beta-adrenergic receptor blocking agent possessing no other autonomic nervous system activity.</li> </ul>			
<b>INDICATIONS</b>			
<ul style="list-style-type: none"> <li>Ventricular dysrhythmias caused by hydrocarbon inhalation/exposure (i.e. huffing).</li> </ul>			
<b>ABSOLUTE CONTRAINDICATIONS</b>			
<ul style="list-style-type: none"> <li>Sinus bradycardia and greater than first degree block.</li> <li>Known hypersensitivity to propranolol hydrochloride.</li> </ul>			
<b>PRECAUTIONS &amp; SIDE EFFECTS</b>			
<ul style="list-style-type: none"> <li>Precautions: Caution against coadministration with epinephrine if in cardiac arrest following huffing.</li> <li>Side effects: May precipitate bronchospasm in asthmatics. May cause or exacerbate bradycardia, heart block, hypotension and CHF.</li> </ul>			
<b>ADMINISTRATION</b>			
IV/IO	<b>Onset:</b> Within 5 minutes.	<b>Peak Effect:</b> 5-10 minutes.	<b>Duration:</b> 2-5 hours.
<b>GUIDELINES CONTAINING PROPRANOLOL</b>			
<ul style="list-style-type: none"> <li>Hydrocarbon Poisoning: Adult &amp; Pediatric</li> </ul>			

DRUG PROFILE		AZDHS	
<b>Rocuronium</b>		5/21/2020	
<b>PHARMACOLOGY &amp; ACTIONS</b>			
<ul style="list-style-type: none"> <li>• Non-depolarizing neuromuscular blocker.</li> <li>• Binds to nicotinic cholinergic receptor sites at the motor end plate. Antagonizes acetylcholine binding at these sites, resulting in neuromuscular blockade.</li> </ul>			
<b>INDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Induction of paralysis to facilitate endotracheal intubation.</li> </ul>			
<b>ABSOLUTE CONTRAINDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Known hypersensitivity.</li> <li>• Rocuronium allergy.</li> </ul>			
<b>PRECAUTIONS &amp; SIDE EFFECTS</b>			
<ul style="list-style-type: none"> <li>• Use ideal body weight for dosing.</li> <li>• Slightly elevates heart rate and blood pressure.</li> <li>• Tachycardia may occur in children.</li> </ul>			
<b>ADMINISTRATION</b>			
IV	<b>Onset:</b> 30–60 seconds	<b>Peak Effect:</b> 1–3 minutes	<b>Duration:</b> 30–60 minutes
<b>GUIDELINES CONTAINING ROCURONIUM</b>			
None.			

DRUG PROFILE		AZDHS	
Sodium bicarbonate 7.5%–8.4%		5/21/2020	
<b>PHARMACOLOGY &amp; ACTIONS</b>			
<ul style="list-style-type: none"> <li>Sodium bicarbonate reacts with hydrogen ions, forming water and carbon dioxide, correcting metabolic acidosis.</li> <li>Increases blood and urinary pH by releasing a bicarbonate ion, which in turn neutralizes hydrogen ion concentrations.</li> </ul>			
<b>INDICATIONS</b>			
<ul style="list-style-type: none"> <li>Cardiac arrest when hyperkalemia or tricyclic antidepressant (TCA) overdose is suspected.</li> <li>Tricyclic antidepressant overdose.</li> <li>Extremity trauma, crush syndrome.</li> </ul>			
<b>ABSOLUTE CONTRAINDICATIONS</b>			
<ul style="list-style-type: none"> <li>Sodium bicarbonate allergy.</li> </ul>			
<b>PRECAUTIONS &amp; SIDE EFFECTS</b>			
<ul style="list-style-type: none"> <li>Administration of sodium bicarbonate may result in metabolic alkalosis, which may be difficult to reverse.</li> </ul>			
<b>ADMINISTRATION</b>			
IV	Onset: immediate	Peak Effect: < 15 minutes	Duration: 1–2 hours
<b>GUIDELINES CONTAINING SODIUM BICARBONATE</b>			
<ul style="list-style-type: none"> <li><b>Extremity Trauma: Adult &amp; Pediatric</b></li> </ul>			

DRUG PROFILE		AZDHS	
<b>Sodium nitrite</b>		01/20/2022	
<b>PHARMACOLOGY &amp; ACTIONS</b>			
<ul style="list-style-type: none"> <li>Interacts with hemoglobin to form methemoglobin which has a higher binding affinity for cyanide and prevents it from entering cells and causing toxicity. Similar mechanism for severe hydrogen sulfide poisoning.</li> </ul>			
<b>INDICATIONS</b>			
<ul style="list-style-type: none"> <li>Antidote for cyanide poisoning (should be used with sodium thiosulfate).</li> <li>Rarely considered for treatment in confirmed hydrogen sulfide poisoning.</li> </ul>			
<b>ABSOLUTE CONTRAINDICATIONS</b>			
<ul style="list-style-type: none"> <li>Hypotension.</li> <li>Hypoxia.</li> </ul>			
<b>PRECAUTIONS &amp; SIDE EFFECTS</b>			
<ul style="list-style-type: none"> <li>Side effects: Hypoxia (cyanosis due to formation of methemoglobin), tachycardia (due to hypoxia), tachypnea, syncope, vasodilation, vomiting, dizziness, headache and flushing.</li> <li>Precaution: Use with caution for significant carbon monoxide poisoning or smoke inhalation.</li> </ul>			
<b>ADMINISTRATION</b>			
IV/IO	<b>Onset:</b> Within minutes.	<b>Peak Effect:</b> ~ 30 minutes.	<b>Duration:</b> ~ 60 minutes.
<b>GUIDELINES CONTAINING SODIUM NITRITE</b>			
<ul style="list-style-type: none"> <li><b>Suspected Cyanide Poisoning: Adult &amp; Pediatric</b></li> <li><b>Sulfide Poisoning: Adult &amp; Pediatric</b></li> </ul>			

DRUG PROFILE		AZDHS	
<b>Sodium nitrite &amp; sodium thiosulfate (combined) (Nithiodote®) 01/20/2022</b>			
<b>PHARMACOLOGY &amp; ACTIONS</b>			
<ul style="list-style-type: none"> <li>• Interacts with hemoglobin to form methemoglobin which has a higher binding affinity for cyanide and prevents it from entering cells and causing toxicity. Similar mechanism for severe hydrogen sulfide poisoning.</li> <li>• When used with sodium nitrite for cyanide poisoning, removes cyanide from cyanide-methemoglobin complex to form thiocyanate, which is then excreted by the kidneys.</li> <li>• Is a reducing agent for some toxic ingestions (see below).</li> </ul>			
<b>INDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Antidote for cyanide poisoning.</li> <li>• See drug profiles for separate indications of sodium nitrite and sodium thiosulfate.</li> </ul>			
<b>ABSOLUTE CONTRAINDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Hypoxia (sodium thiosulfate is okay, sodium nitrite is not).</li> <li>• Hypotension (sodium thiosulfate is okay, sodium nitrite is not).</li> </ul>			
<b>PRECAUTIONS &amp; SIDE EFFECTS</b>			
<ul style="list-style-type: none"> <li>• Side effect: May cause hypoxia (cyanosis due to formation of methemoglobin), tachycardia (due to hypoxia), tachypnea, syncope, vasodilation, vomiting, dizziness, headache and flushing.</li> <li>• Side effect: May cause hypotension, vomiting, headache and muscle cramps.</li> <li>• Precaution: Use with caution for significant carbon monoxide poisoning or smoke inhalation.</li> </ul>			
<b>ADMINISTRATION</b>			
IV/IO	<b>Onset:</b> Within 5 mins.	<b>Peak Effect:</b> 5-10 minutes.	<b>Duration:</b> 2-5 hours.
<b>GUIDELINES CONTAINING SODIUM NITRITE &amp; SODIUM THIOSULFATE (COMBINED)</b>			
<ul style="list-style-type: none"> <li>• <b>Suspected Cyanide Poisoning: Adult &amp; Pediatric</b></li> </ul>			



DRUG PROFILE		AZDHS	
Sodium thiosulfate		01/20/2022	
<b>PHARMACOLOGY &amp; ACTIONS</b>			
<ul style="list-style-type: none"> <li>When used with sodium nitrite for cyanide poisoning, removes cyanide from cyanide-methemoglobin complex to form thiocyanate, which is then excreted by the kidneys.</li> <li>Is a reducing agent for some toxic ingestions (see below).</li> </ul>			
<b>INDICATIONS</b>			
<ul style="list-style-type: none"> <li>Antidote for cyanide poisoning (when used with sodium nitrite).</li> <li>Can be used following ingestion of bromates, chlorates, chromates and iodine.</li> </ul>			
<b>ABSOLUTE CONTRAINDICATIONS</b>			
<ul style="list-style-type: none"> <li>None.</li> </ul>			
<b>SIDE EFFECTS</b>			
<ul style="list-style-type: none"> <li>Nausea, vomiting, headache and muscle cramps.</li> </ul>			
<b>ADMINISTRATION</b>			
IV/IO	<b>Onset:</b> Within minutes.	<b>Peak Effect:</b> Varies based on dose.	<b>Duration:</b> Varies based on dose.
<b>GUIDELINES CONTAINING SODIUM THIOSULFATE</b>			
<ul style="list-style-type: none"> <li><b>Suspected Cyanide Poisoning: Adult &amp; Pediatric</b></li> </ul>			

DRUG PROFILE		AZDHS	
Succinylcholine		5/21/2020	
<b>PHARMACOLOGY &amp; ACTIONS</b>			
<ul style="list-style-type: none"> <li>• Depolarizing neuromuscular blocker.</li> <li>• Acts on the motor end plate receptors, producing depolarization or fasciculations, and inhibiting subsequent neuromuscular transmission for the duration of the medication (short acting).</li> <li>• Muscles are unable to be stimulated by acetylcholine.</li> </ul>			
<b>INDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Induction of paralysis to facilitate endotracheal intubation.</li> </ul>			
<b>ABSOLUTE CONTRAINDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Malignant hyperthermia (may result in irreversible trismus).</li> <li>• Known or suspected hyperkalemia.</li> <li>• Penetrating eye injury (increases intraocular pressure).</li> <li>• Inability to control the airway and/or support ventilations.</li> <li>• Paraplegia/quadraplegia.</li> <li>• Musculoskeletal disorders such as muscular dystrophy, spinal muscular atrophy.</li> <li>• Prolonged immobilization.</li> <li>• Stroke with residual motor dysfunction.</li> <li>• Succinylcholine allergy.</li> </ul>			
<b>PRECAUTIONS &amp; SIDE EFFECTS</b>			
<ul style="list-style-type: none"> <li>• Use with caution in patients with anticipated difficult airway.</li> <li>• Has no effect on consciousness - sedatives should be used in conjunction with succinylcholine administration.</li> </ul>			
<b>ADMINISTRATION</b>			
IV	<b>Onset:</b> 30–60 seconds	<b>Peak Effect:</b> 1–3 minutes	<b>Duration:</b> 7–10 minutes
<b>GUIDELINES CONTAINING SUCCINYLBCHOLINE</b>			
None.			

DRUG PROFILE		AZDHS	
Tetracaine		5/21/2020	
<b>PHARMACOLOGY &amp; ACTIONS</b>			
<ul style="list-style-type: none"><li>Local ocular anesthetic that blocks sodium ion channels required for the initiation and conduction of neuronal impulses, thereby effecting corneal local anesthesia.</li><li>Used as a topical ophthalmic anesthetic to facilitate ocular irrigation and to provide analgesia.</li></ul>			
<b>INDICATIONS</b>			
<ul style="list-style-type: none"><li>Chemical ocular exposure requiring irrigation.</li></ul>			
<b>ABSOLUTE CONTRAINDICATIONS</b>			
<ul style="list-style-type: none"><li>Tetracaine allergy.</li></ul>			
<b>PRECAUTIONS &amp; SIDE EFFECTS</b>			
<ul style="list-style-type: none"><li>Each bottle is single use only.</li><li>Patients should be advised that their eyes will be insensitive up to 20 minutes and that care should be taken to avoid ocular contact.</li></ul>			
<b>ADMINISTRATION</b>			
Eye Drops	<b>Onset:</b> immediate	<b>Peak Effect:</b> 15–30 seconds	<b>Duration:</b> 10–20 minutes
<b>GUIDELINES CONTAINING TETRACAINE</b>			
<ul style="list-style-type: none"><li><b>Dermal Chemical Burns: Adult &amp; Pediatric</b></li></ul>			

DRUG PROFILE		AZDHS	
<b>Thiamine (vitamin B1)</b>		5/21/2020	
<b>PHARMACOLOGY &amp; ACTIONS</b>			
<ul style="list-style-type: none"> <li>• Required for carbohydrate metabolism, converts glucose into energy.</li> <li>• Chronic alcohol intake interferes with the absorption, intake, and utilization of thiamine.</li> <li>• Patients who are malnourished, or have chronic alcohol abuse, may develop Wernicke's encephalopathy if given IV glucose without concomitant administration of thiamine.</li> </ul>			
<b>INDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Thiamine should precede the administration of Dextrose or Glucagon in any adult patient if there is any evidence of malnutrition or alcohol abuse.</li> </ul>			
<b>ABSOLUTE CONTRAINDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Thiamine allergy.</li> </ul>			
<b>PRECAUTIONS &amp; SIDE EFFECTS</b>			
<ul style="list-style-type: none"> <li>• None in prehospital setting.</li> </ul>			
<b>ADMINISTRATION</b>			
IV	<b>Onset:</b> hours	<b>Peak Effect:</b> 3–5 days	<b>Duration:</b> unknown
<b>GUIDELINES CONTAINING THIAMINE</b>			
None.			

DRUG PROFILE		AZDHS	
<b>Tranexamic Acid (TXA)</b>		9/16/2021	
<b>PHARMACOLOGY &amp; ACTIONS</b>			
<ul style="list-style-type: none"> <li>• A synthetic derivative of lysine that inhibits fibrinolysis by blocking the lysine binding sites on plasminogen.</li> <li>• A competitive inhibitor of plasminogen activation, which produces antifibrinolytic effects preserving and stabilizing fibrins matrix structure thus preventing clot breakdown rather than promoting new clot formation.</li> <li>• Reversibly binds to plasminogen at the lysine binding site, thus preventing the binding of plasmin to fibrin.</li> <li>• Inhibits the activation of plasminogen to plasmin, thereby preventing fibrinolysis and the breakdown of clots.</li> </ul>			
<b>INDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Unstable patients with evidence of hemorrhagic shock.</li> </ul>			
<b>ABSOLUTE CONTRAINDICATIONS</b>			
<ul style="list-style-type: none"> <li>• Suspected CVA, MI or PE.</li> <li>• Hypersensitivity to medication.</li> </ul>			
<b>PRECAUTIONS &amp; SIDE EFFECTS</b>			
<ul style="list-style-type: none"> <li>• This medication should not replace guideline-based patient management of TBI or other trauma.</li> <li>• Hypotension (if administered via IVP).</li> <li>• Must be administered within 3 hours of injury.</li> <li>• History of blood clots.</li> <li>• Giddiness, allergic dermatitis, diarrhea, nausea, vomiting, blurred vision.</li> </ul>			
<b>ADMINISTRATION</b>			
IV/IO	<b>Onset:</b> 5-15 minutes	<b>Peak Effect:</b> 1-2 minutes	<b>Duration:</b> 3 hours
<b>GUIDELINES CONTAINING TRANEXAMIC ACID</b>			
<ul style="list-style-type: none"> <li>• <b>General Trauma Management: Adult and Pediatric</b></li> <li>• <b>External Hemorrhage Management: Adult &amp; Pediatric</b></li> </ul>			